Therapeutic Response

CD20 + status confers therapeutic sensitivity to Cyclophosphamide in combination with Doxorubicin, Prednisone, Rituximab, and Vincristine in patients with Burkitt Lymphoma.

Statements

Source and description

Rituxan (rituximab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.